Description: Invivyd, formerly Adagio Therapeutics (Nasdaq: ADGI), is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company is generating a robust pipeline of products for use in both prevention and treatment of disease. NVD200, Invivyd’s first antibody combination product for COVID-19, is expected to enter the clinic in Q1 2023. Invivyd’s most advanced pipeline candidate is adintrevimab, an investigational monoclonal antibody which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Adintrevimab is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. The company also has multiple discovery stage candidates for the prevention of seasonal influenza.
Home Page: www.invivyd.com
IVVD Technical Analysis
1601 Trapelo Road
Waltham,
MA
02451
United States
Phone:
781 819 0080
Officers
| Name | Title |
|---|---|
| Mr. David Hering M.B.A. | CEO & Director |
| Ms. Jill Andersen J.D. | Chief Legal Officer & Corp. Sec. |
| Ms. Laura Walker Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Frederick W. Driscoll | Interim CFO, Principal Financial Officer & Principal Accounting Officer |
| Dr. Rebecca Dabora Ph.D. | Chief Technology & Manufacturing Officer |
| Kyra Rosow Faircloth | VP of Gov. Affairs, Advocacy & Corp. Communication |
| Dr. Peter C. Schmidt M.D., M.Sc. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4995 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-08-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 101 |